In what is normally a slow–growing category in the 0.5%-3.0% range for year–over–year performance, the internal analgesics category witnessed much stronger–than–average growth rates in 2020. Consumers stocked up on pain relievers and fever reducers to be prepared for coronavirus. The overall internal analgesics category witnessed sales growth of more than 6.0%, with the Tylenol brand up nearly 40% and Motrin IB (both by Johnson & Johnson) up nearly 100% compared to 2019 sales. Continue reading→